Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma - Test2 - elhamkhani - TriplyDB

Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma

Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma

http://www.wikidata.org/entity/Q33854012

about

The role of HDAC6 in cancer HEF1-dependent Aurora A activation induces disassembly of the primary cilium Histone deacetylase inhibitors: Potential in cancer therapy Clinical use and applications of histone deacetylase inhibitors in multiple myeloma Clinical developments in the treatment of relapsed or relapsed and refractory multiple myeloma: impact of panobinostat, the first-in-class histone deacetylase inhibitor Novel agents for multiple myeloma to overcome resistance in phase III clinical trials Histone deacetylase 6 plays a role as a distinct regulator of diverse cellular processes New and emerging HDAC inhibitors for cancer treatment Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally.Clinical use of proteasome inhibitors in the treatment of multiple myeloma Novel therapeutic strategies for multiple myeloma Histone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancy Aggresome formation and neurodegenerative diseases: therapeutic implications Development of a histone deacetylase 6 inhibitor and its biological effects Reversible inhibitor of p97, DBeQ, impairs both ubiquitin-dependent and autophagic protein clearance pathways Parkin-mediated K63-linked polyubiquitination targets misfolded DJ-1 to aggresomes via binding to HDAC6 Synergistic apoptosis induction in leukemic cells by the phosphatase inhibitor salubrinal and proteasome inhibitors Inhibition of inducible heat shock protein-70 (hsp72) enhances bortezomib-induced cell death in human bladder cancer cells HDAC6 inhibition results in tau acetylation and modulates tau phosphorylation and degradation in oligodendrocytes The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivo Carbamate prodrug concept for hydroxamate HDAC inhibitors.Lymphocyte chemotaxis is regulated by histone deacetylase 6, independently of its deacetylase activity.RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma.TANDEM: a two-stage approach to maximize interpretability of drug response models based on multiple molecular data types.Targeting the UPS as therapy in multiple myeloma.Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors.Panobinostat in lymphoid and myeloid malignancies.Deacetylase inhibitors: an advance in myeloma therapy?Clinical Pharmacokinetics and Pharmacodynamics of Panobinostat.IIp45 inhibits cell migration through inhibition of HDAC6 Discovery of a highly synergistic anthelmintic combination that shows mutual hypersusceptibility TPPP/p25 promotes tubulin acetylation by inhibiting histone deacetylase 6 SAHA and S116836, a novel tyrosine kinase inhibitor, synergistically induce apoptosis in imatinib-resistant chronic myelogenous leukemia cells.Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation.New strategies in the treatment of multiple myeloma.Tubacin suppresses proliferation and induces apoptosis of acute lymphoblastic leukemia cells.Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights.Protein quality control during erythropoiesis and hemoglobin synthesis A novel class of small molecule inhibitors of HDAC6.Knock down of heat shock protein 27 (HspB1) induces degradation of several putative client proteins.

P2860

Q21296746-31AB3446-2C22-4A04-874F-864EA872126F Q24647111-AE06EB5B-1513-41C9-A12E-63F0A6991533 Q24649025-36FE02D0-36D5-46CF-BDF0-386B1BEB01FB Q26745930-311BC036-B34A-403D-92BA-1CBD833C70D1 Q26747768-4AC67124-DFE9-4514-A104-55B087B60248 Q26822754-CE77FC2E-CD5C-4C2D-BA77-C18A0E456A02 Q26830233-5FE9D9C7-AA39-4500-B554-EFC8932EADFC Q27022413-9AFEF038-A168-45FF-A50C-9F501B22F516 Q27919716-3233F497-6A90-474D-B371-4D024E45FB86 Q28080999-45356B8E-FCAF-4F1D-8DAD-347247F6F227 Q28081590-F2874067-C626-4C64-9DC1-CDB85F91ED20 Q28082536-392E7C2E-7C34-4B34-B128-27999185F431 Q28265926-F6D683C4-3B62-45A6-8B4B-C6818546DF1D Q28298272-A9B44DC9-222C-4D5E-B8B9-B1F5855B80E7 Q28306744-F916C06A-4DC5-4248-90AC-741098326276 Q28397050-39BF6E26-2ADD-4E84-9C3F-B1DA96981578 Q28474489-0D466549-B897-41DF-A830-CB549C50D8E1 Q28534720-FA0464DE-9E6D-421B-BB08-A21E012BBEEE Q28575023-3653CAE5-77A6-4CDB-A387-872D985C4620 Q28751751-6032F948-BA12-429F-BCDB-9504FB8698A8 Q30318440-EDA14A46-3291-4D5E-BDC9-F3D8BE5E1C60 Q30477707-FB348F88-FCEE-4C5B-A5FC-F4C5D037F465 Q30488936-3CCB502F-72FE-4429-960C-5F40D040521D Q31126284-05398547-BEAE-413B-8EF7-AE2327F1BC52 Q33384287-45C67D8F-C977-49C4-9A20-776D96B20059 Q33390876-6226E10E-6675-416B-920B-E3D925289B18 Q33408889-664B8DE3-40AF-45C1-9FDD-193C7B39065D Q33438321-D61FBA5A-5A8D-49FA-958B-593F5D75C533 Q33443179-F3D1C7F1-89B5-462F-A69F-6EBCBDA1F87A Q33661940-ACD583AD-520C-4542-B0FA-9DFB46F49E05 Q33778375-6F96CCDC-D839-4DDF-B092-2FB1D023BE52 Q33885326-7C2948D2-2B4E-4B2D-8C4B-59BFDB0DC352 Q33911230-62BB9098-DD18-4032-860D-324059FE50BC Q33937865-73F760AE-9102-46DB-8818-40F2833E455D Q33958520-90937907-0D4B-4686-9267-46936137F3B7 Q33959401-748CF723-296B-4033-AC71-89CFA3D80549 Q33983255-A0135A30-35B3-4B46-9E26-67730FC5C293 Q34060218-384AAA09-4B37-4145-9BA2-457FB8358244 Q34065056-6CE866EA-77B8-4176-A797-82982FAD4E65 Q34125213-463DFD5D-E6CA-4024-8BB0-F100878F5A7C

P2860

Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma

http://www.wikidata.org/entity/Q33854012

description

2005 nî lūn-bûn

@nan

2005 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Small-molecule inhibition of p ...... r activity in multiple myeloma

@ast

Small-molecule inhibition of p ...... r activity in multiple myeloma

@en

type

label

Small-molecule inhibition of p ...... r activity in multiple myeloma

@ast

Small-molecule inhibition of p ...... r activity in multiple myeloma

@en

prefLabel

Small-molecule inhibition of p ...... r activity in multiple myeloma

@ast

Small-molecule inhibition of p ...... r activity in multiple myeloma

@en

P1433

Q33854012-166E0534-1DD4-4E57-8B50-29CEED8B2BEC

P1476

Q33854012-FC599BF1-BBA1-4866-AFC7-0C78CF6FAA69

P2093

Q33854012-136AAA69-CBD3-4AC7-A997-426A4A03902D

Q33854012-6F978B77-F7AB-48B3-A7B8-3086C25998FA

Q33854012-7196C754-7960-4E3F-ABEA-0F7910C57097

Q33854012-88361972-C6B0-4922-8F8F-A385C4E5B788

Q33854012-B493F0A0-201D-4F78-B722-0D6C72B303F3

P2860

Q33854012-0906572F-0029-4A69-B65B-97CDBB1847D7

Q33854012-0ADBC135-AF16-478F-AFF2-2217CC252EC5

Q33854012-0BB3AED2-4140-4B5E-8C33-A7C9ECEC5605

Q33854012-1AC7994F-93D2-4614-A41B-ACD0DA884357

Q33854012-24421F67-FF9D-440D-A286-AD40CD2AD49D

Q33854012-251041EC-4800-446E-8288-D143E2778F13

Q33854012-251391F7-5412-4A6C-9F4C-8C3161EBA49C

Q33854012-26268E45-6F5C-45ED-A1FE-4DFB7639E860

Q33854012-2D093693-95C9-400A-8D7E-73D1FEF55B52

Q33854012-31FE310B-BF34-4C24-8758-C33824433350

P304

Q33854012-5AC94E4F-F192-4801-9EF7-41D658662D72

P31

Q33854012-9BB52786-998D-4744-A7EF-4DFD941BFFB3

P356

Q33854012-F58AEC3B-2651-4E86-A86B-F845149E5E73

P407

Q33854012-563F61C0-67B4-44C6-B475-5E4E05F06974

P433

Q33854012-BE9A60B4-FEC3-4ABC-B9C4-0988ADB6A7C1

P478

Q33854012-B177A662-7F0F-48E1-9B47-5A8B6527142F

P50

Q33854012-4CE41B97-4591-4BF2-AD88-71B808419290

Q33854012-A7D71B0B-1FC4-41CE-9096-E4841E23045C

P577

Q33854012-95F45434-6969-4C30-A4C9-BF7AE8064FF7

P5875

Q33854012-5C4B618C-AEAA-4A18-9583-CFF6B73E37B9

P698

Q33854012-D3D8A2E7-4F9E-4EAF-8092-2403740C1AA6

P932

Q33854012-4D5602DB-C7BF-40D0-8B1C-04651BB4AB93

P356

PNAS.0503221102

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Small-molecule inhibition of p ...... r activity in multiple myeloma

@en

P2093

Dharminder Chauhan

http://www.w3.org/2001/XMLSchema#string

James E Bradner

http://www.w3.org/2001/XMLSchema#string

Jason Wong

http://www.w3.org/2001/XMLSchema#string

Stuart L Schreiber

http://www.w3.org/2001/XMLSchema#string

Teru Hideshima

http://www.w3.org/2001/XMLSchema#string

P2860

The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress

Aggresomes, inclusion bodies and protein aggregation

Multidimensional chemical genetic analysis of diversity-oriented synthesis-derived deacetylase inhibitors using cell-based assays.

A phase 2 study of bortezomib in relapsed, refractory myeloma.

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.

NF-kappa B as a therapeutic target in multiple myeloma.

Hassles with taking out the garbage: aggravating aggresomes.

Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation

Molecular mechanisms of novel therapeutic approaches for multiple myeloma.

P304

8567-8572

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0503221102

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

102

http://www.w3.org/2001/XMLSchema#string

P50

Kenneth C Anderson

Paul G Richardson

P577

2005-06-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7805418

http://www.w3.org/2001/XMLSchema#string

P698

15937109

http://www.w3.org/2001/XMLSchema#string

P932

1150844

http://www.w3.org/2001/XMLSchema#string